Merck licenses ovarian cancer candidate to AstraZeneca

AstraZeneca secured the rights to develop, produce and commercialize Merck & Co.'s experimental drug MK-1775, which is in midstage trials for ovarian cancer. The deal entitles Merck to $50 million upfront, potential milestone fees and sales royalties. "The compound has demonstrated encouraging clinical efficacy data, and we intend to study it in a range of cancer types where there is a high unmet medical need," said Susan Galbraith, head of AstraZeneca's oncology innovative medicines unit.

View Full Article in:

PharmaTimes (U.K.) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC